Source: International Congress 2019 – Assessment and management of immune-mediated interstitial lung diseases
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
V. Tzilas (Athens, Greece), A. Tzouvelekis (Athens, Greece), E. Bouros (Athens, Greece), M. Katsaras (Athens, Greece), M. Ntassiou (Athens, Greece), T. Karampitsakos (Athens, Greece), D. Bouros (Athens, Greece). Antifibrotic treatment in 18 patients with chronic Hypersensitivity Pneumonitis. 4733

Member's Comments

No comment yet.

Related content which might interest you: Outcomes of immunosuppressive therapy in chronic hypersensitivity pneumonitis Source: ERJ Open Res, 3 (3) 00016-2017; 10.1183/23120541.00016-2017 Year: 2017 Rituximab for the treatment of chronic hypersensitivity pneumonitis Source: International Congress 2015 – Interstitial lung diseases I Year: 2015 Hypersensitivity pneumonitis associated with the use of temozolomide Source: Eur Respir J 2009; 33: 931-934 Year: 2009 Chronic inhaled corticosteroids in patients with bronchiectasis who suffer an exacerbation Source: International Congress 2016 – Possible phenotypes of bronchiectasis and exacerbations Year: 2016 Diagnosis and management of chronic fibrotic hypersensitivity pneumonitis Source: Virtual Congress 2020 – Diagnosis and management of chronic fibrotic hypersensitivity pneumonitis Year: 2020 Chronic Hypersensitivity Pneumonitis and mortality: impact of comorbidities Source: Virtual Congress 2020 – Clinical issues in granulomatous lung diseases Year: 2020 Long-term safety of combination therapy with nintedanib and pirfenidone in Japanese patients with IPF Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Hypersensitivity pneumonitis associated with temozolomide Source: Eur Respir J 2009; 33: 526 Year: 2009 Hypersensitivity pneumonitis caused by oral aspirin Source: Annual Congress 2009 - Clinical aspects of inflammatory airways diseases Year: 2009 Efficacy of short-term prednisolone treatment in patients with chronic eosinophilic pneumonia Source: Eur Respir J 2015; 45: 1624-1631 Year: 2015 Effect of 2-Year therapy with Roflumilast in severe systemic inflammation in COPD with metabolic syndrome Source: International Congress 2019 – Advances in COPD pharmacology Year: 2019 Chronic Hypersensitivity pneumonitis: risks factors and therapeutic options Source: Virtual Congress 2020 – Interstitial lung diseases Year: 2020 Methotrexate as a single agent for the treatment of patients with progressive pulmonary sarcoidosis Source: International Congress 2015 – Sarcoidosis: clinical Year: 2015 Impact Prognostic impact of comorbidities in patients with chronic Hypersensitivity Pneumonitis Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: from the bench to the bedside Year: 2018 Anti-inflammatory therapy for sarcoidosis patients Source: Annual Congress 2013 –Diffuse parenchymal lung disease III Year: 2013 Impact of BAL lymphocytosis and honeycombing presence on corticosteroid treatment effect in Fibrotic Hypersensitivity Pneumonitis Source: International Congress 2019 – Connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis: what’s new? Year: 2019 Evaluation of methotrexate in the treatment of severe asthma Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis Year: 2015 Intravenous pulse doses of high-dose corticosteroid and cyclophosphamide in acute exacerbation of idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Cyclophosphamide in steroid-refractory hypersensitivity pneumonitis and non-classifiable interstitial lung disease Source: International Congress 2017 – Novel and old entities Year: 2017 Mechanisms of exercise limitation in patients with chronic hypersensitivity pneumonitis Source: ERJ Open Res, 4 (3) 00043-2018; 10.1183/23120541.00043-2018 Year: 2018